Translational results from the Swedish randomised phase III, TEX trial show that breast cancer relapse characteristics display aggressive features, with an over-representation of ER-negative, HER2-positive and highly proliferative tumours.

The molecular subtype of breast cancer metastases significantly influences post-relapse survival, according to the study findings presented by Dr Nicholas Tobin of the Karolinska Institute, Stockholm, Sweden.

Click here to read the article in full.

Source: ESMO